Novel drug candidate with a first-in-class mechanism for smoking cessation & abstinence, advancing into clinical development

Dr. Nurulain T. Zaveri, PhD, FAAPS, is the first recipient of inaugural 2020 Alice E. Till Recognition for Advancement of Women in Pharmaceutical Sciences, from the American Association of Pharmaceutical Sciences (AAPS).

Dr. Zaveri is a Fellow of the AAPS, and a founding leader for the Women in Pharmaceutical Sciences community at AAPS.

"AT-121, a small molecule agonist of two opioid receptors, mediates analgesia without opioid-associated side effects in nonhuman primates"                                                                            - Science Translational Medicine

Science Translational Medicine

Cover Story: No Pain, all gain

Science

"Rhesus monkeys given AT-121 experienced 100-fold greater pain relief than the same dose of morphine provided"

A Promising Alternative to Opioid Pain Medications

"[AT-121] represents a potential advance toward the goal of nonaddicting analgesics that are at least as effective as opioids but without typical opioid liabilities"

Live Science

"Nonaddictive Opioid Alternative Shows Promise in Monkey Study"

The Guardian

"Opioid Crisis: breakthrough in hunt for non-addictive painkiller"

Scientific American

"A still-experimental drug demonstrates the qualities of an ideal painkiller in a test in monkeys"

Dr. Nurulain T. Zaveri, PhD

President and Chief Scientific Officer